Tiziana Life Sciences plc: Publication of Research Note

Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA) has announced a new analyst research note published by H.C. Wainwright & Co., available on their website. The company focuses on developing novel therapies for oncology, inflammation, and infectious diseases. Tiziana is advancing its pipeline, including phase 2 studies for foralumab, a human anti-CD3 monoclonal antibody targeting Crohn’s Disease and multiple sclerosis. They are also accelerating development of an anti-IL6R monoclonal antibody aimed at treating IL6-induced inflammation, particularly in COVID-19 patients.

Positive

• Initiating phase 2 studies for foralumab targeting Crohn's Disease and multiple sclerosis.
• Foralumab is the only fully human anti-CD3 mAb in clinical development globally.
• Accelerating development of anti-IL6R mAb for COVID-19 treatment.

Negative

• None.

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:
United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder	+44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner	+44 (0)20 7213 0880
Optiva Securities Limited (Broker)
Robert Emmet	+44 (0)20 3981 4173
United States:
Investors
Dave Gentry
RedChip Companies Inc.
001 407 – 491 – 4498
Dave@redchip.com

 

FAQ

What is the latest news about Tiziana Life Sciences (TLSA)?

Tiziana Life Sciences has released a new analyst research note and is advancing its clinical studies.

What therapies is Tiziana Life Sciences developing?

Tiziana is developing therapies for oncology, inflammation, and infectious diseases, including foralumab for autoimmune conditions.

When will Tiziana start phase 2 studies for foralumab?

Tiziana will shortly initiate phase 2 studies for orally and nasally administered foralumab.

What is foralumab and its significance in Tiziana's pipeline?

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, targeting multiple autoimmune diseases.

What action is Tiziana taking regarding COVID-19 treatment?

Tiziana is accelerating the development of an anti-IL6R monoclonal antibody specifically for treating COVID-19 patients.